Maintenance Rituximab Not Effective for Aggressive B-Cell Lymphoma

No benefit was observed for relapsed patients who were in remission after receiving reinduction therapy and autologous stem cell transplantation.

Improving outcomes for patients with relapsed or refractory aggressive B-cell lymphoma remains an important yet only partially met goal. To address this clinical challenge, investigators for the multicenter, phase III CORAL study previously compared two induction regimens — R-ICE (rituximab, ifosfamide, carboplatin, and etoposide) versus R-DHAP (rituximab, dexamethasone, high-dose cytarabine, and cisplatin) — in patients with diffuse large B-cell lymphoma (DLBCL). Chemosensitive patients then received high-dose therapy and underwent consolidative autologous stem cell transplantation (ASCT). Results showed that the 3-year overall survival rate was similar between the R-ICE and R-DHAP groups (51% and 47%, respectively; JW Oncol Hematol Aug 17…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee